Ionis Pharma rises on better-than-expected quarterly results
19/02/2025 12:30
** Drugmaker Ionis Pharmaceuticals' IONS.O shares rise
4.5% to $33.40 premarket
** IONS posts Q4 sales of $227 mln, above analysts' est of
$137.6 mln - LSEG
** Co reports Q4 loss of 66 cents/share vs analysts' est
loss of $1.12/share - LSEG
** Co expects 2025 rev to be over $600 mln; analysts on avg
expect 2025 rev to be $676 mln - LSEG
** As of December 31, 2024, IONS had cash, cash equivalents
and short-term investments of $2.3 bln
** Co forecasts cash, cash equivalents and short-term
investments of about $1.7 bln for 2025
** IONS fell ~34% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors